Surgery and tile-based radiation therapy versus surgery and stereotactic radiation for newly diagnosed brain metastases (ROADS): a randomized, open-label, phase 3 trial
Source: View publication →
In patients with newly diagnosed brain metastases requiring surgical resection, immediate intraoperative placement of cesium-131 collagen tiles significantly improved surgical bed recurrence and overall survival compared to standard post-operative stereotactic radiotherapy.
Key Findings
Study Design
Study Limitations
Clinical Significance
The ROADS trial establishes intraoperative cesium-131 tile-based radiation therapy (TBRT) as a highly effective new standard-of-care option for newly diagnosed operable brain metastases. By bypassing the traditional 2- to 4-week delay associated with postoperative SRT, TBRT ensures 100% compliance with local radiation and prevents the well-documented treatment attrition gap where a proportion of patients fail to receive planned radiation. Ultimately, TBRT yielded unprecedented local control and a surprisingly substantial overall survival benefit without increasing toxicity compared to standard stereotactic radiation.
Historical Context
Historically, surgical resection of large or symptomatic brain metastases was followed by whole-brain radiation therapy (WBRT) to prevent local recurrence. Due to severe neurocognitive toxicities associated with WBRT, post-operative cavity stereotactic radiosurgery (SRS/SRT) emerged as the preferred modern standard of care. However, standard SRT requires a mandatory post-operative healing period of 2 to 4 weeks, during which microscopic residual disease can progress, and up to 20% of patients experience clinical decline or fail to return for radiotherapy. To address this logistical and therapeutic gap, bioresorbable cesium-131 collagen tiles (GammaTile) were developed to deliver focal brachytherapy immediately upon tumor removal. The phase 3 ROADS trial serves as the landmark validation of this technology, being the first randomized controlled trial to directly compare TBRT against the contemporary SRT standard.
Guided Discussion
High-yield insights from every perspective
What are the radiobiologic and practical advantages of using intraoperative Cesium-131 brachytherapy tiles compared to post-operative stereotactic radiotherapy for brain metastases?
Key Response
This tests foundational knowledge of radiation oncology. Cs-131 brachytherapy delivers highly targeted, low-energy radiation continuously from inside the surgical cavity, minimizing dose to healthy brain tissue. Practically, it eliminates the need for patients to wait for wound healing before starting radiation, thereby preventing the microscopic tumor growth that can occur during the typical 2 to 4 week delay required for external beam radiotherapy.
In patients undergoing surgical resection for brain metastases, how does the elimination of the post-operative waiting period for radiation via Cs-131 tiles alter standard post-operative management and complication monitoring?
Key Response
Residents must understand that standard post-operative stereotactic radiotherapy is delayed to allow surgical wound healing. While Cs-131 tiles streamline care and prevent tumor repopulation during this gap, residents must be vigilant in monitoring for unique local complications, such as impaired wound healing directly over the surgical bed and early-onset radiation necrosis, which present differently than complications from delayed external beam radiation.
Given the survival and local control benefits seen in the ROADS trial, what specific tumor characteristics, cavity geometries, and anatomical locations would make a patient the ideal candidate for Cs-131 tiles versus fractionated post-operative stereotactic radiotherapy?
Key Response
Fellows must apply advanced clinical judgment. While tiles offer excellent local control, large or highly irregular surgical cavities may not allow for uniform tile apposition, leading to cold spots. Furthermore, tumors resected near eloquent structures or the brainstem might still be better managed with fractionated post-operative radiotherapy to leverage the radiobiological advantage of normal tissue repair between fractions, minimizing the risk of severe neurologic deficits.
Adopting intraoperative Cs-131 tiles requires significant coordination between neurosurgery and radiation oncology. What are the key logistical and safety barriers to implementing this protocol, and how does it shift the paradigm of multidisciplinary neuro-oncology care?
Key Response
Attendings need to consider systems-based practice. Implementing this requires handling radioactive isotopes in the operating room, new radiation safety protocols for OR staff, and shifting the radiation oncologist's workflow into the surgical suite. This represents a major logistical hurdle but ultimately centralizes care, potentially reducing total treatment time and improving patient compliance by eliminating separate post-operative radiation visits.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The ROADS trial utilizes an open-label design. How might performance bias and detection bias influence the evaluation of surgical bed recurrence, and what statistical models should be employed to properly account for competing risks in this specific patient population?
Key Response
Because surgical implants cannot be blinded, there is a high risk of detection bias when evaluating local recurrence versus radiation necrosis on post-operative MRI. A PhD researcher would emphasize the necessity of a Blinded Independent Central Review (BICR) for imaging. Furthermore, since brain metastasis patients frequently die from systemic disease progression before local recurrence occurs, researchers must use competing risk regression models (like the Fine-Gray model) rather than standard Kaplan-Meier estimates to avoid overestimating local failure rates.
As an editor evaluating the ROADS trial, what concerns might you raise regarding the control arm's adherence to contemporary stereotactic radiotherapy standards, and how does the lack of blinded imaging review threaten the validity of the primary endpoint?
Key Response
A critical reviewer would scrutinize the control arm to ensure that the stereotactic radiotherapy provided (dose, fractionation, and margin expansion) reflects current state-of-the-art practice rather than outdated, suboptimal techniques that would artificially inflate the experimental arm's effect size. Additionally, without blinded independent central review, investigator bias in distinguishing true recurrence from post-treatment radiation effect (pseudoprogression) severely threatens the validity of the local recurrence endpoint.
Current ASTRO and NCCN guidelines strongly recommend post-operative stereotactic radiosurgery to the surgical cavity to improve local control. Based on the ROADS trial, does intraoperative brachytherapy warrant a Category 1 recommendation, and what specific toxicity data are required before it replaces SRS as the standard of care?
Key Response
Guideline committees must evaluate if a single Phase 3 trial provides sufficient evidence to change the standard of care. While the overall survival benefit is compelling, committees would require robust, long-term comparative data on the rates of radiation necrosis, wound dehiscence, and leptomeningeal disease. They would likely introduce Cs-131 tiles as a Category 2A or 1 alternative option in select patients, rather than a blanket replacement for post-operative SRS, until real-world safety data matures.
Clinical Landscape
Noteworthy Related Trials
Patchell Trial
Tested
Postoperative WBRT
Population
Patients with a single completely resected brain metastasis
Comparator
Observation
Endpoint
Tumor recurrence in the brain
NCCTG N107C/CEC.3
Tested
Postoperative Stereotactic Radiosurgery (SRS)
Population
Patients with 1-4 brain metastases and 1 resected cavity
Comparator
Whole-brain radiotherapy (WBRT)
Endpoint
Cognitive-deterioration-free survival
Mahajan et al. Trial
Tested
Postoperative SRS
Population
Patients with completely resected 1-3 brain metastases
Comparator
Observation
Endpoint
Time to local recurrence
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis